This Underrated Biotech May Have Just Demonstrated the Longevity of Its Leading Drug
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 12 2025
0mins
Should l Buy APLS?
Source: Benzinga
Post Hoc Analysis Results: Apellis Pharmaceuticals announced that a post hoc analysis of the GALE extension study showed Syfovre significantly delayed geographic atrophy lesion growth by approximately 1.5 years compared to projected sham treatments, with monthly and every-other-month dosing resulting in 31% and 27% reductions in lesion growth, respectively.
Market Performance and Analyst Insights: Despite a 4% quarter-over-quarter growth in Syfovre demand and a net product revenue of $150.9 million, Apellis' stock has faced challenges due to a lack of copay assistance. Analysts view this as a buying opportunity, highlighting Syfovre's potential for long-term market share growth against competitors.
Long-Term Outlook: Analysts believe that Syfovre's superior efficacy over Astellas Pharma's Izervay positions it well for significant market share as physicians prioritize effectiveness over safety, indicating a positive long-term outlook for the drug.
Stock Performance: Apellis' stock was trading up by 2.52% to $20.01, reflecting a potential value disconnect as investors focus on short-term competitive pressures rather than the drug's long-term prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy APLS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on APLS
Wall Street analysts forecast APLS stock price to rise
14 Analyst Rating
9 Buy
5 Hold
0 Sell
Moderate Buy
Current: 19.990
Low
19.00
Averages
31.69
High
48.00
Current: 19.990
Low
19.00
Averages
31.69
High
48.00
About APLS
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan) is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and the United Kingdom.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Apellis (APLS) Q4 2025 Earnings Call Transcript
See More
Apellis Pharmaceuticals Reports Q4 2025 Financial Results
- Financial Overview: Apellis Pharmaceuticals reported a net loss of $58.9 million for Q4 2025, an increase from a $36.4 million loss in the same period of 2024, indicating ongoing challenges in achieving profitability.
- Revenue Performance: The company generated $199.9 million in revenue, a 5.9% year-over-year decline, although it beat market expectations by $0.46 million, reflecting a struggle with sales growth.
- Cash Position: As of December 31, 2025, Apellis had $466 million in cash and cash equivalents, which is projected to be sufficient to fund operations until profitability, demonstrating financial stability.
- Market Index Inclusion: Apellis Pharmaceuticals will be included in the S&P SmallCap 600 index, marking an increase in its recognition in the capital markets and potentially attracting more investor interest.
See More
Apellis Pharmaceuticals Set to Announce Q4 Earnings on February 24
- Earnings Announcement: Apellis Pharmaceuticals is set to release its Q4 2023 earnings report on February 24 before market open, with consensus EPS estimates at -$0.39, reflecting a 34.5% year-over-year decline, indicating significant profitability challenges for the company.
- Revenue Decline: The anticipated revenue for Q4 is $199.44 million, representing a 6.1% year-over-year decrease, which highlights the competitive pressures the company faces and could impact investor confidence moving forward.
- Estimate Revision Trends: Over the past three months, EPS estimates have seen one upward revision and three downward adjustments, while revenue estimates have experienced six upward revisions and five downward changes, indicating analyst divergence on the company's performance and potential stock price volatility.
- Market Index Inclusion: Apellis Pharmaceuticals will join TTM Technologies and Dutch Bros in the S&P 400 Index, while Amneal and Apellis will be part of the S&P SmallCap 600, which may enhance its market visibility and investment appeal.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting varying market perspectives on these companies.
- Market Dynamics Observation: While specific stock names are not mentioned, changes in analyst ratings typically influence investor decisions, potentially leading to price volatility in the affected stocks.
- Investor Attention: Investors considering buying OKLO stock should pay attention to analysts' opinions to make more informed investment decisions, especially amid increasing market uncertainty.
- Impact of Rating Changes: Analyst rating adjustments not only affect short-term market sentiment but may also have profound implications for the long-term stock performance of the companies involved, necessitating close monitoring of subsequent developments.
See More
Apellis Pharmaceuticals' Empaveli Approved, Projected $508 Million Sales by 2033
- Market Potential Unveiled: Apellis Pharmaceuticals' Empaveli received FDA approval in 2025 as the first treatment for C3 glomerulopathy, which is expected to significantly enhance the company's revenue outlook over the coming years.
- Early Commercial Performance: In Q3, Empaveli generated $27 million in U.S. net product revenue, with 267 new patient start forms recorded since its late July approval, indicating a 5% market penetration and strong acceptance.
- Competitive Advantage: The broader label of Empaveli is driving early uptake, with management asserting its efficacy surpasses Novartis' Fabhalta, projecting peak U.S. sales of $508 million by 2033, which could further elevate the company's valuation.
- Future Catalysts: Analysts noted that the anticipated filing for Syfovre's prefilled syringe in the first half of 2026 could lead to market share expansion and overall market growth, with potential impacts expected in 2027.
See More
Bank of America Upgrades Apellis Pharmaceuticals to Buy, Highlights Strong Empaveli Launch
- Strong Market Performance: Since receiving FDA approval for Empaveli in July for C3 glomerulopathy, Apellis has recorded 267 new patient start forms, indicating robust market demand and product acceptance.
- Payer Progress: Management reports no full denials to date, suggesting that Empaveli's broader label and superior efficacy compared to Novartis' Fabhalta have facilitated rapid market penetration.
- EU Approval Boost: Apellis' partner Sobi recently received EU approval for the drug against C3G and IC-MPGN, further enhancing Empaveli's competitive position in international markets.
- Growth Potential: With the price target unchanged at $28 per share, analysts believe there is room for continued upside as momentum builds in the coming quarters.
See More
Apellis (APLS) Q4 2025 Earnings Call Transcript
See More
Apellis Pharmaceuticals Reports Q4 2025 Financial Results
- Financial Overview: Apellis Pharmaceuticals reported a net loss of $58.9 million for Q4 2025, an increase from a $36.4 million loss in the same period of 2024, indicating ongoing challenges in achieving profitability.
- Revenue Performance: The company generated $199.9 million in revenue, a 5.9% year-over-year decline, although it beat market expectations by $0.46 million, reflecting a struggle with sales growth.
- Cash Position: As of December 31, 2025, Apellis had $466 million in cash and cash equivalents, which is projected to be sufficient to fund operations until profitability, demonstrating financial stability.
- Market Index Inclusion: Apellis Pharmaceuticals will be included in the S&P SmallCap 600 index, marking an increase in its recognition in the capital markets and potentially attracting more investor interest.
See More
Apellis Pharmaceuticals Set to Announce Q4 Earnings on February 24
- Earnings Announcement: Apellis Pharmaceuticals is set to release its Q4 2023 earnings report on February 24 before market open, with consensus EPS estimates at -$0.39, reflecting a 34.5% year-over-year decline, indicating significant profitability challenges for the company.
- Revenue Decline: The anticipated revenue for Q4 is $199.44 million, representing a 6.1% year-over-year decrease, which highlights the competitive pressures the company faces and could impact investor confidence moving forward.
- Estimate Revision Trends: Over the past three months, EPS estimates have seen one upward revision and three downward adjustments, while revenue estimates have experienced six upward revisions and five downward changes, indicating analyst divergence on the company's performance and potential stock price volatility.
- Market Index Inclusion: Apellis Pharmaceuticals will join TTM Technologies and Dutch Bros in the S&P 400 Index, while Amneal and Apellis will be part of the S&P SmallCap 600, which may enhance its market visibility and investment appeal.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting varying market perspectives on these companies.
- Market Dynamics Observation: While specific stock names are not mentioned, changes in analyst ratings typically influence investor decisions, potentially leading to price volatility in the affected stocks.
- Investor Attention: Investors considering buying OKLO stock should pay attention to analysts' opinions to make more informed investment decisions, especially amid increasing market uncertainty.
- Impact of Rating Changes: Analyst rating adjustments not only affect short-term market sentiment but may also have profound implications for the long-term stock performance of the companies involved, necessitating close monitoring of subsequent developments.
See More
Apellis Pharmaceuticals' Empaveli Approved, Projected $508 Million Sales by 2033
- Market Potential Unveiled: Apellis Pharmaceuticals' Empaveli received FDA approval in 2025 as the first treatment for C3 glomerulopathy, which is expected to significantly enhance the company's revenue outlook over the coming years.
- Early Commercial Performance: In Q3, Empaveli generated $27 million in U.S. net product revenue, with 267 new patient start forms recorded since its late July approval, indicating a 5% market penetration and strong acceptance.
- Competitive Advantage: The broader label of Empaveli is driving early uptake, with management asserting its efficacy surpasses Novartis' Fabhalta, projecting peak U.S. sales of $508 million by 2033, which could further elevate the company's valuation.
- Future Catalysts: Analysts noted that the anticipated filing for Syfovre's prefilled syringe in the first half of 2026 could lead to market share expansion and overall market growth, with potential impacts expected in 2027.
See More
Bank of America Upgrades Apellis Pharmaceuticals to Buy, Highlights Strong Empaveli Launch
- Strong Market Performance: Since receiving FDA approval for Empaveli in July for C3 glomerulopathy, Apellis has recorded 267 new patient start forms, indicating robust market demand and product acceptance.
- Payer Progress: Management reports no full denials to date, suggesting that Empaveli's broader label and superior efficacy compared to Novartis' Fabhalta have facilitated rapid market penetration.
- EU Approval Boost: Apellis' partner Sobi recently received EU approval for the drug against C3G and IC-MPGN, further enhancing Empaveli's competitive position in international markets.
- Growth Potential: With the price target unchanged at $28 per share, analysts believe there is room for continued upside as momentum builds in the coming quarters.
See More
